FOI_6715

Internal Reference Number: FOI_6715

Date Request Received: 02/08/2022 00:00:00

Date Request Replied To: 23/08/2022 00:00:00

This response was sent via: By Email

Request Summary: Nivolumab Questions

Request Category: Companies


Question Number 1: In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma? - Nivolumab (monotherapy) - Nivolumab AND Ipilimumab (combination) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Answer To Question 1: We do not treat these tumour types at this Trust with systemic treatment.

Question Number 2: In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma? - Nivolumab (monotherapy) - Nivolumab + Ipilimumab - Nivolumab + Cabozantinib - Avelumab + Axitinib *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Answer To Question 2: We do not treat these tumour types at this Trust with systemic treatment.

Question Number 3: In the past 3 months, how many patients have been initiated* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)? - Nivolumab - Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Answer To Question 3: Nivolumab <5 patients No patients with pembrolizumab in combination.

Question Number 4: Does your trust participate in any clinical trials for the treatment of Melanoma? If so, please provide the name of each active trial, and the number of patients taking part.

Answer To Question 4: no

Question Number 5: Does your trust participate in any clinical trials for the treatment of Renal Cell Carcinoma? If so, please provide the name of each active trial, and the number of patients taking part.

Answer To Question 5: no

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.